Sumy C. Daeufer
Partner | She/Her/Hers
Overview
Sumy Daeufer’s background in life sciences makes her particularly adept at guiding clients through complex transactions that drive value in all phases of drug development from R&D to commercial product licensing. As lead transactional counsel she helps clients navigate and negotiate strategic product research, development and commercialization transactions, technology and product licensing, academic research collaborations and licensing and commercial product manufacturing and supply chain transactions.
Career & Education
- Associate General Counsel, Discovery and Development Group, Millennium Pharmaceuticals, Inc. (now Takeda Pharmaceutical Company Limited)
- Manager of the Discovery and Development Group within the legal department
- Member of the committee responsible for managing Millennium’s product pipeline
- Business team member for the company’s marketed products
- Lead in-house attorney for the development and commercialization alliance for Millennium’s first oncology drug
- Counsel, Pharmaceuticals North America, Warner-Lambert Company (now Pfizer Inc)
- Responsible for corporate, contract and general legal matters for the Parke-Davis pharmaceuticals division in North America and South Africa
- Corporate Lawyer, AmLaw 50 firm
- Focused on secured financing, M&A transactions and initial public offerings
- Associate General Counsel, Discovery and Development Group, Millennium Pharmaceuticals, Inc. (now Takeda Pharmaceutical Company Limited)
- Yale University, B.A., summa cum laude
- Yale Law School, J.D.
- Massachusetts
- New York
Representative Matters
Sumy’s experience includes the following representative matters in her capacity as co-founder and Principal at Faber Daeufer & Itrato PC, prior to joining Crowell Life Sciences in 2025:
- Represented a leading pharmaceutical company in the acquisition and in-license of a Hemophilia A program and in vivo gene editing technology from a biotechnology company Novo Nordisk’s acquisition and in-license of 2seventy’s Hemophilia A program and megaTAL in vivo gene editing technology
- Alnylam in its
- License Agreement for novel siRNA for potential treatment of polycythemia vera
- Research collaboration to discover RNAi therapeutics to promote the regrowth of functional liver cells
- Participation in the Medicines Manufacturing Innovation Centre Grand Challenge 3 (GC3) consortium with multiple industry partners
- Research and development collaboration to develop RNAi therapeutics for COVID-19 and other coronaviruses
- Research and development collaboration for new treatments of nonalcoholic steatohepatitis (NASH) and other liver diseases
- Research and development collaboration to develop RNAi therapeutics for chronic hepatitis B virus and other infectious diseases
- Expansion of its strategic alliance and broad cross-licensing arrangement with a prominent biotechnology company developing RNA-targeted therapeutics
- License and collaboration agreement with a leading cardiovascular focused biopharmaceutical company for siRNA molecules targeting PCSK9
- Exclusive global alliance with a leading cardiovascular focused biopharmaceutical company for the development and commercialization of a therapeutic program for hypercholesterolemia
- Strategic collaboration to develop an RNAi therapeutic for liver cancer in China
- Exclusive out-license agreement for global rights to a pre-clinical ophthalmology program between a pharmaceutical and a biotechnology company Development and option agreement between an epigenomic therapeutic company and a Canadian based biotechnology firm focused on deliver systems for nucleic acid therapeutics
- Sale and license of a Phase 2 anti-CD37 non-Hodgkin lymphoma (NHL) antibody-drug conjugate (ADC) product program between a biotechnology and a pharmaceutical company. Exclusive license of a recombinant immunoglobulin product between an antibody-based biologics company and a global biopharmaceutical company
- Research and development collaboration for bispecific therapeutic antibodies between two clinical stage biopharmaceutical companies
- A leading American biotechnology company in its
- Research collaboration to develop subcutaneous formulations of proprietary hemophilia products
- In-license and transfer of an antibody discovery technology platform
- Drug discovery collaboration in Parkinson’s research
- Drug discovery collaboration for kinase inhibitors for inflammatory disease
- An immunotherapy company’s exclusive license of clinical-stage T-cell therapy technology from a renowned cancer research institution
- Research and collaboration and license agreement between a pharmaceutical company and a global healthcare company for autoimmune and chronic inflammatory disorders
